Interleukin Genetics, Inc  

(Public, OTCMKTS:ILIU)   Watch this stock  
Find more results for PINK:ILIU
0.000 (0.00%)
Jul 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.25 - 0.25
52 week 0.21 - 0.46
Open 0.25
Vol / Avg. 500.00/6,691.00
Mkt cap 30.63M
P/E     -
Div/yield     -
EPS -0.07
Shares 122.52M
Beta 1.81
Inst. own 46%
May 14, 2014
Q1 2014 Interleukin Genetics Earnings Conference Call
May 14, 2014
Q1 2014 Interleukin Genetics Earnings Release

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -341.39% -290.50%
Operating margin -341.80% -271.59%
EBITD margin - -262.15%
Return on average assets -74.36% -107.83%
Return on average equity -148.79% -
Employees 27 -
CDP Score - -


135 Beaver Street
United States - Map
+1-781-3980700 (Phone)
+1-781-3980720 (Fax)


Interleukin Genetics, Inc. is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company´┐Żs business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.

Officers and directors

James M. Weaver Independent Chairman of the Board
Age: 49
Kenneth S. Kornman Ph.D,DDS President, Chief Executive Officer, Chief Scientific Officer, Director
Age: 65
Eliot M. Lurier CPA Chief Financial Officer, Treasurer
Age: 55
Scott Snyder Chief Marketing Officer
Age: 52
Joseph M. Landstra Director
Lionel Carnot Independent Director
Roger C. Colman Independent Director
William C. Mills III Independent Director
Age: 57
Dayton C. Misfeldt Independent Director
Age: 40